Miltefosine repositioning: A review of potential alternative antifungal therapy.

Autor: Spadari CC; Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Borba-Santos LP; Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Rozental S; Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Ishida K; Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: ishidakelly@usp.br.
Jazyk: angličtina
Zdroj: Journal de mycologie medicale [J Mycol Med] 2023 Nov; Vol. 33 (4), pp. 101436. Date of Electronic Publication: 2023 Sep 20.
DOI: 10.1016/j.mycmed.2023.101436
Abstrakt: Fungal infections are a global health problem with high mortality and morbidity rates. Available antifungal agents have high toxicity and pharmacodynamic and pharmacokinetic limitations. Moreover, the increased incidence of antifungal-resistant isolates and the emergence of intrinsically resistant species raise concerns about seeking alternatives for efficient antifungal therapy. In this context, we review literature data addressing the potential action of miltefosine (MFS), an anti-Leishmania and anticancer agent, as a repositioning drug for antifungal treatment. Here, we highlight the in vitro and in vivo data, MFS possible mechanisms of action, case reports, and nanocarrier-mediated MFS delivery, focusing on fungal infection therapy. Finally, many studies have demonstrated the promising antifungal action of MFS in vitro, but there is little or no data on antifungal activity in vertebrate animal models and clinical trials, so have a need to develop more research for the repositioning of MFS as an antifungal therapy.
Competing Interests: Declaration of Competing Interest The authors have no conflict of interest.
(Copyright © 2023 SFMM. Published by Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: